Pricing Log in Create free account
Friday 6 November 2026 Export PVLA’s income statement to Excel — free account

Palvella Therapeutics, Inc.

PVLA Healthcare Biotechnology

Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.

EPS
−76.7%
Free cash flow
−136.4%

Quarter to June 2026, against a year earlier

174.63 17.78 +11.34%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
2/9
Altman Z
−11.49
Beneish M
1.44
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Palvella Therapeutics, Inc. (PVLA) Total debt

Alert me on Total debt

Palvella Therapeutics, Inc.'s total debt at the end of fiscal 2022 was $13.1M, down 12.0% from $14.9M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $12.3M. Palvella Therapeutics, Inc. ranks 232nd of 569 Biotechnology companies by total debt.

Total debt, annual

Embed this chart

Annual newest first

Period Total debt Change
FY2022 $13.1M (12.00%)
FY2021 $14.9M (12.22%)
FY2020 $17.0M 4.59%
FY2019 $16.2M —

Quarterly newest first

Period Total debt Change
Sep 2023 $12.3M (4.18%)
Jun 2023 $12.8M (1.99%)
Mar 2023 $13.1M (0.11%)
Dec 2022 $13.1M 7.25%
12 more quarters

Total debt against peers

Company Total debt
BHVN Biohaven Ltd. compare $264.3M
ADMA ADMA Biologics Inc compare $198.9M
VCEL Vericel Corporation compare $85.1M
VERA Vera Therapeutics, Inc. compare $75.2M
AUPH Aurinia Pharmaceuticals Inc compare $39.0M
PVLA Palvella Therapeutics, Inc. $12.3M
CLDX Celldex Therapeutics, Inc. compare $1.2M
PHVS Pharvaris N.V. compare $559.6K
IMNM Immunome, Inc. compare $228.0K

What Total debt is

Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.

Long Term Debt (Total) + Current Part of Debt

The full definition of Total debt →

More on PVLA